Momelotinib (also known as CYT387, a JAK1/2 inhibitor) showed favorable therapeutic effects on myelofibrosis in preclinical trials by reducing multiple myeloma proliferation, inducing apoptosis of JAK2-dependent haematopoietic cells, and regulating inflammatory cytokines303. The gene discussed is JAK2; the disease is myelofibrosis.